Switching from Neutral Protamine Hagedorn Insulin to Insulin Glargine 300 UmL Improves Glycaemic Control and Reduces Hypoglycaemia Risk: Results of a Multicentre, Prospective, Observational Study
Joint Authors
Klupa, Tomasz
Wolnik, B.
Wiza, D.
Szczepanik, T.
Syta, A.
Source
Issue
Vol. 2020, Issue 2020 (31 Dec. 2020), pp.1-8, 8 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2020-04-08
Country of Publication
Egypt
No. of Pages
8
Main Subjects
Abstract EN
Type 2 diabetes mellitus (T2DM) is a major cause of morbidity and mortality worldwide and is an important public health issue.
A significant proportion of insulin-treated patients with T2DM do not reach target glycated haemoglobin (HbA1c) values, which ultimately increases their risk of long-term microvascular and macrovascular complications.
One potential option to improve diabetes control in these patients may be the use of new insulin formulations including second-generation basal insulin analogues such as insulin glargine 300 U/mL (Gla-300).
Several published randomised controlled trials have assessed the clinical effectiveness of Gla-300, mostly versus insulin glargine 100 U/mL as well as insulin degludec.
However, there is limited information about the real-world effectiveness of Gla-300 when patients are transitioned directly from neutral protamine Hagedorn (NPH) human basal insulin.
The primary objective of this study was to evaluate the effectiveness of Gla-300, defined as the percentage of participants with an HbA1c reduction of ≥0.5%, 6 months after switching from NPH insulin, in participants with T2DM.
Secondary objectives included the safety assessment based on the percentage of patients experiencing ≥1 episodes and the number of hypoglycaemic episodes by category: severe, symptomatic, symptomatic confirmed, diurnal or nocturnal, change in body weight, and insulin dose.
A total of 469 participants completed the 6-month observation period.
Mean baseline HbA1c was 9.19%.
The percentage of participants with a ≥0.5% improvement in HbA1c from baseline was 71.7% at 6 months.
Mean HbA1c decreased at 3 and 6 months by 0.77% (±0.98) and 1.01% (±1.12), respectively (p<0.00001 versus baseline), while fasting glycaemia decreased by 32 mg/dL and 37 mg/dL, respectively (p<0.00001 versus baseline).
There were moderate increases in the doses of both Gla-300 and, if used, short-acting insulins during the 6 months of observation.
The percentage of participants with ≥1 hypoglycaemia event during the preceding 4 weeks decreased significantly from baseline to 3 and 6 months, as did the proportion with symptomatic hypoglycaemia at night (p<0.00001 versus baseline).
No participants had severe hypoglycaemia after a switch to Gla-300.
Body mass, waist and hip circumferences, and waist : hip ratio did not change significantly.
In conclusion, this large, prospective, observational study demonstrated that switching from NPH insulin to Gla-300 resulted in a significant improvement in HbA1c, with only a moderate increase in insulin dose, a decreased risk of hypoglycaemia, and no increase in body weight.
American Psychological Association (APA)
Wolnik, B.& Wiza, D.& Szczepanik, T.& Syta, A.& Klupa, Tomasz. 2020. Switching from Neutral Protamine Hagedorn Insulin to Insulin Glargine 300 UmL Improves Glycaemic Control and Reduces Hypoglycaemia Risk: Results of a Multicentre, Prospective, Observational Study. Journal of Diabetes Research،Vol. 2020, no. 2020, pp.1-8.
https://search.emarefa.net/detail/BIM-1183469
Modern Language Association (MLA)
Wolnik, B.…[et al.]. Switching from Neutral Protamine Hagedorn Insulin to Insulin Glargine 300 UmL Improves Glycaemic Control and Reduces Hypoglycaemia Risk: Results of a Multicentre, Prospective, Observational Study. Journal of Diabetes Research No. 2020 (2020), pp.1-8.
https://search.emarefa.net/detail/BIM-1183469
American Medical Association (AMA)
Wolnik, B.& Wiza, D.& Szczepanik, T.& Syta, A.& Klupa, Tomasz. Switching from Neutral Protamine Hagedorn Insulin to Insulin Glargine 300 UmL Improves Glycaemic Control and Reduces Hypoglycaemia Risk: Results of a Multicentre, Prospective, Observational Study. Journal of Diabetes Research. 2020. Vol. 2020, no. 2020, pp.1-8.
https://search.emarefa.net/detail/BIM-1183469
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1183469